论文部分内容阅读
目的探讨EGFR基因敏感突变肺癌患者TKIs治疗耐药后后续疗效差别。方法收集EGFR基因敏感突变、吉非替尼治疗出现获得性耐药并且临床资料完整的非小细胞肺癌患者27例。分析耐药后采取的治疗措施及无疾病进展时间。结果 27例患者中位无疾病进展时间为8.2月[95%CI(4.5,11.9)]。后续治疗模式可分为四类,包括标准化疗、靶向治疗、化疗联合靶向治疗及联合放疗的综合治疗。四组的PFS分别为5.6月、8.2月、10.1月及9.1月,然而四组间PFS差异无统计学意义(P=0.953>0.05)。结论对于EGFR-TKIs获得性耐药的肺腺癌患者,不论采取何种治疗措施,疗效相仿。
Objective To investigate the difference of efficacy after treatment of TKIs in patients with EGFR gene sensitive mutation lung cancer. Methods Twenty-seven patients with non-small cell lung cancer who were sensitive to EGFR gene mutation and were treated with gefitinib and had complete clinical data were collected. Analysis of the treatment measures taken after resistance and no disease progression time. Results The median progression-free progression time was 8.2 months [95% CI (4.5, 11.9)] in 27 patients. Follow-up treatment patterns can be divided into four categories, including standard chemotherapy, targeted therapy, chemotherapy combined with targeted therapies and combined radiotherapy combined treatment. The PFS of the four groups were 5.6 months, 8.2 months, 10.1 months and 9.1 months, respectively. However, there was no significant difference in PFS between the four groups (P = 0.953> 0.05). Conclusion The efficacy of EGFR-TKIs acquired resistance in patients with lung cancer, no matter what kind of treatment, the effect is similar.